FHTX Stock Overview
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Foghorn Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.38 |
| 52 Week High | US$18.12 |
| 52 Week Low | US$5.32 |
| Beta | 1.88 |
| 1 Month Change | 49.11% |
| 3 Month Change | 2.82% |
| 1 Year Change | -40.27% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -53.75% |
Recent News & Updates
Shareholder Returns
| FHTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.5% | 0.7% | 2.3% |
| 1Y | -40.3% | 7.1% | -9.7% |
Return vs Industry: FHTX underperformed the US Biotechs industry which returned 10.5% over the past year.
Return vs Market: FHTX underperformed the US Market which returned -8.5% over the past year.
Price Volatility
| FHTX volatility | |
|---|---|
| FHTX Average Weekly Movement | 12.7% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: FHTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: FHTX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 119 | Adrian H. Gottschalk | https://foghorntx.com |
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma.
Foghorn Therapeutics Inc. Fundamentals Summary
| FHTX fundamental statistics | |
|---|---|
| Market Cap | US$350.30m |
| Earnings (TTM) | -US$109.14m |
| Revenue (TTM) | US$15.76m |
22.2x
P/S Ratio-3.2x
P/E RatioIs FHTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FHTX income statement (TTM) | |
|---|---|
| Revenue | US$15.76m |
| Cost of Revenue | US$99.87m |
| Gross Profit | -US$84.12m |
| Other Expenses | US$25.02m |
| Earnings | -US$109.14m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.61 |
| Gross Margin | -533.83% |
| Net Profit Margin | -692.64% |
| Debt/Equity Ratio | 0% |
How did FHTX perform over the long term?
See historical performance and comparison